Insulet (NASDAQ:PODD) was upgraded by equities researchers at UBS Group from a “market perform” rating to an “outperform” rating in a report released on Monday, The Fly reports.

Other equities analysts also recently issued research reports about the stock. Morgan Stanley lifted their target price on shares of Insulet from $55.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, November 3rd. Barclays began coverage on shares of Insulet in a research note on Friday, September 15th. They set an “overweight” rating and a $65.00 target price for the company. Leerink Swann reissued an “outperform” rating and set a $74.00 target price (up previously from $65.00) on shares of Insulet in a research note on Thursday, October 12th. Zacks Investment Research raised shares of Insulet from a “sell” rating to a “hold” rating and set a $68.00 target price for the company in a research note on Thursday, October 12th. Finally, Canaccord Genuity raised shares of Insulet from a “hold” rating to a “buy” rating and lifted their target price for the stock from $50.00 to $65.00 in a research note on Wednesday, November 1st. One equities research analyst has rated the stock with a sell rating, seven have issued a hold rating and twelve have assigned a buy rating to the company’s stock. Insulet currently has an average rating of “Buy” and an average target price of $62.53.

Shares of Insulet (NASDAQ PODD) traded down $3.04 during midday trading on Monday, reaching $75.08. 1,101,800 shares of the company were exchanged, compared to its average volume of 750,133. Insulet has a fifty-two week low of $38.19 and a fifty-two week high of $78.65. The company has a market capitalization of $4,550.00, a P/E ratio of -150.16 and a beta of 1.58. The company has a debt-to-equity ratio of 4.65, a current ratio of 4.88 and a quick ratio of 4.42.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, November 2nd. The medical instruments supplier reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.06. Insulet had a negative net margin of 6.66% and a negative return on equity of 43.85%. The business had revenue of $121.80 million during the quarter, compared to the consensus estimate of $114.02 million. During the same quarter last year, the firm earned ($0.05) earnings per share. Insulet’s quarterly revenue was up 28.4% on a year-over-year basis. analysts anticipate that Insulet will post -0.43 earnings per share for the current year.

In related news, Director James C. Mullen purchased 2,500 shares of Insulet stock in a transaction on Monday, November 13th. The stock was acquired at an average cost of $67.45 per share, for a total transaction of $168,625.00. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 2.60% of the company’s stock.

Large investors have recently bought and sold shares of the business. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in Insulet by 11.4% in the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,302 shares of the medical instruments supplier’s stock worth $118,000 after purchasing an additional 235 shares during the period. SG Americas Securities LLC acquired a new stake in Insulet in the second quarter worth $180,000. RNC Capital Management LLC acquired a new stake in Insulet in the second quarter worth $225,000. Trexquant Investment LP acquired a new stake in Insulet in the third quarter worth $242,000. Finally, Amalgamated Bank grew its holdings in Insulet by 5.7% in the second quarter. Amalgamated Bank now owns 7,476 shares of the medical instruments supplier’s stock worth $384,000 after purchasing an additional 406 shares during the period.

COPYRIGHT VIOLATION WARNING: “Insulet (PODD) Upgraded at UBS Group” was published by Daily Political and is owned by of Daily Political. If you are accessing this piece on another domain, it was stolen and republished in violation of US & international copyright & trademark laws. The original version of this piece can be read at https://www.dailypolitical.com/2018/01/10/insulet-podd-upgraded-at-ubs-group.html.

About Insulet

Insulet Corporation is engaged in the development, manufacturing and sale of the OmniPod Insulin Management System (the OmniPod System), an insulin delivery system for people with insulin-dependent diabetes. The Omnipod System features a self-adhesive disposable tubeless Omnipod device, which is worn on the body for approximately three days at a time and its wireless companion, the handheld Personal Diabetes Manager (PDM).

The Fly

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.